ASTRAZENECA PLC (ZEG.DE) Stock Price, Forecast & Analysis
Europe - FRA:ZEG - GB0009895292 - Common Stock
ZEG.DE Key Statistics, Chart & Performance
The current stock price of ZEG.DE is 154.6 EUR. In the past month the price increased by 6.8%. In the past year, price increased by 21.97%.
ZEG.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.84 | 219.19B | ||
| SNW.DE | SANOFI | 11.85 | 219.41B | ||
| SAN.PA | SANOFI | 11.83 | 218.97B | ||
| MRK.DE | MERCK KGAA | 16.75 | 50.33B | ||
| 1MRK.MI | MERCK KGAA | 13.27 | 49.11B | ||
| UCB.BR | UCB SA | 35.61 | 44.46B | ||
| 1BAYN.MI | BAYER AG-REG | 5.68 | 27.43B | ||
| BAYN.DE | BAYER AG-REG | 5.68 | 27.45B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.52 | 10.93B | ||
| IPN.PA | IPSEN | 12.72 | 10.95B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.06 | 8.89B | ||
| VIRP.PA | VIRBAC SA | 20.56 | 2.99B |
Related stock screener links
About ZEG.DE
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Company Info
ASTRAZENECA PLC
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE GB
Employees: 94300
Phone: 442073045000
ASTRAZENECA PLC / ZEG.DE FAQ
What does ZEG do?
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
What is the current price of ZEG stock?
The current stock price of ZEG.DE is 154.6 EUR. The price increased by 0.85% in the last trading session.
Does ZEG stock pay dividends?
ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 1.81%. The yearly dividend amount is currently 2.56.
What is the ChartMill rating of ASTRAZENECA PLC stock?
ZEG.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the expected growth for ZEG stock?
The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 9.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for ZEG stock?
ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.
ZEG.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is one of the better performing stocks in the market, outperforming 84.57% of all stocks.
ZEG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. ZEG.DE has an excellent profitability rating, but there are concerns on its financial health.
ZEG.DE Financial Highlights
Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 6.82. The EPS increased by 4.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.17% | ||
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| Debt/Equity | 0.61 |
ZEG.DE Forecast & Estimates
33 analysts have analysed ZEG.DE and the average price target is 156.15 EUR. This implies a price increase of 1% is expected in the next year compared to the current price of 154.6.
For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 9.58% for ZEG.DE